Jaguar Health/$JAGX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Jaguar Health
Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
Ticker
$JAGX
Sector
Primary listing
Employees
47
Headquarters
Website
Jaguar Health Metrics
BasicAdvanced
$603k
-
-$262.29
0.03
-
Price and volume
Market cap
$603k
Beta
0.03
52-week high
$7.89
52-week low
$0.91
Average daily volume
88k
Financial strength
Current ratio
0.647
Quick ratio
0.242
Long term debt to equity
-190.592
Total debt to equity
-546.18
Interest coverage (TTM)
-31.03%
Profitability
EBITDA (TTM)
-23.598
Gross margin (TTM)
85.06%
Net profit margin (TTM)
-115.39%
Operating margin (TTM)
-86.26%
Revenue per employee (TTM)
$630,000
Management effectiveness
Return on assets (TTM)
-35.86%
Return on equity (TTM)
2,337.58%
Valuation
Price to revenue (TTM)
0.006
Price to book
-0.03
Price to tangible book (TTM)
-0.01
Price to free cash flow (TTM)
-0.025
Free cash flow yield (TTM)
-3,968.25%
Free cash flow per share (TTM)
-39.679
Growth
Revenue change (TTM)
155.96%
Earnings per share change (TTM)
-91.99%
3-year revenue growth (CAGR)
37.79%
Jaguar Health News
AllArticlesVideos
Jaguar Health Reports Positive Consumer and Veterinary Market Research Findings Supporting Commercial Opportunity for Neonorm Dog
Accesswire·4 days ago
Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF) Due to Microvillus Inclusion Disease (MVID)
Accesswire·1 week ago
Presentation at ESPGHAN 2026 Describes Additional Groundbreaking Results of Evaluation of Jaguar Health's Crofelemer as Adjunctive Oral Therapy for the Treatment of Pediatric Intestinal Failure (IF)
Accesswire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.